Impact of generic drug discount programs on managed care organizations

American Journal of Pharmacy Benefits

Volumn 3, Issue 1, 2011, Pages 45-53

  Patel, Harshali K ^a   Dwibedi, Nilanjana ^a   Omojasola, Anthony ^b   Sansgiry, Sujit S ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMFEBUTAMONE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ATENOLOL; CARVEDILOL; CEFALEXIN; CITALOPRAM; FEXOFENADINE; FLUOXETINE; GABAPENTIN; GENERIC DRUG; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LEVOTHYROXINE; LISINOPRIL; METFORMIN; MEVINOLIN; OMEPRAZOLE; ONDANSETRON; PAROXETINE; PRAVASTATIN; SALBUTAMOL; SERTRALINE; SIMVASTATIN; TRAMADOL; WARFARIN;

COST CONTROL; CROSS-SECTIONAL STUDY; DRUG COST; DRUG MARKETING; DRUG PROGRAM; HEALTH CARE COST; HUMAN; MANAGED CARE; PHARMACEUTICAL CARE; PRESCRIPTION; REVIEW;

EID: 79951488883     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Snow D Jr. Maximising generic utilization: the power of pharmacy benefit management. Journal of Generic Medicines. 2007;5(1):27-38.
2. Briesacher B, Andrade S, Fouyazi H, Chan K. Medication adherence and use of generic drug therapies. Am J Managed Care. 2009;15(7):450-456.
3. Skipoff M. PBMs are driving up generic utilization. Drug Topics. August 8, 2005. http://drugtopics.modernmedicine.com/drugtopics/Supplements/PBMs-aredriving-up-generic-utilization/ArticleStandard/Article/detail/172234. Accessed July 12, 2009.
4. Hartman M, Martin A, McDonnell P, Catlin A; National Health Expenditure Accounts Team. National health spending in 2007: slower drug spending contributes to lowest rate of overall growth since 1998. Health Aff (Millwood). 2009;28(1):246-261.
5. Walmart. Wal-Mart bringing $4 generic prescriptions to working families. Affordable Health Care. http://www.acrohrsolutions.com/forms/Walmart%20Prescription%20Drugs.pdf. Accessed March 2, 2009.
6. Herrick D. Shopping for drugs: 2007. National Center for Policy Analysis; 2006.
7. Herrick D. Wal-Mart drug discounts increase competition and lower prices. National Center for Policy Analysis. January 11, 2007. http://cdhc.ncpa.org/commentaries/wal-mart-drug-discounts-increase-competition-and-lower-prices. Accessed March 2, 2009.
8. Dwibedi N, Sansgiry S. Assessment of generic drug discount programs offered by large chain pharmacies in the United States. Journal of Generic Medicines. 2009;6(4):363-368.
9. Agwunobi J, London PA. Removing costs from the health care supply chain: lessons from mass retail. Health Aff (Millwood). 2009;28(5):1336-1342.
10. Carroll J. Could a Wal-Mart PBM succeed? Manag Care. 2008;17(4):36-38.
11. Knight A. Beyond transparency: the $4 dollar effect. February 6, 2010. http://www.rxtimes.com/beyond-transparency-the-4-dollar-effect/. Accessed February 15, 2010.
12. Wal-Mart scores big with $4 generic prescription offer. Drug Store News. August 13, 2007. http://findarticles.com/p/articles/mi_m3374/is_10_29/ai_n27354187/. Accessed June 27, 2009.
13. Wal-Mart press room. Wal-Mart launches phase three of $4 prescription program. May 5, 2008. http://walmartstores.com/pressroom/news/8248.aspx. Accessed June 27, 2009.
14. Davey N. Store wars. Next Generation Pharmaceutical. http://www.ngpharma.com/article/Store-wars/. Accessed February 15, 2010.
15. McWilliams G, Martinez B. Wal-Mart cuts prices for many generic drugs to $4. The Wall Street Journal. 2006:22.
16. Purvis L. Strategies to increase generic drug utilization and associated savings. Insight on the Issues. AARP Public Policy Institute. December 16, 2008. http://assets.aarp.org/rgcenter/health/i16_generics.pdf. Accessed January 2, 2011.
17. Chain Drug Review. Top 100 chains by pharmacy dollar volume. August 29, 2005. http://findarticles.com/p/articles/mi_hb3007/is_14_27/ai_n29203823/. Accessed August 29, 2009.
18. Hartman M, Martin A, Nuccio O, Catlin A; National Health Expenditure Accounts Team. Health spending growth at a historic low in 2008. Health Affairs (Millwood). 2010;29(1):147-155.
19. SDI/Verispan. 2008 Top 200 generic drugs by retail dollars. Drug Topics. http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/192009/597086/article.pdf. Accessed June 15, 2009.
20. SDI/Verispan. 2008 Top 200 generic drugs by total prescriptions. Drug Topics. http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/222009/599844/article.pdf. Accessed June 15, 2009.
21. Kaiser Family Foundation. Prescription Drug Trends. September 2008. http://www.kff.org/rxdrugs/upload/3057_07.pdf. Accessed April 22, 2009.
22. National Center for Health Statistics. Healthcare expenditure in the USA. Medical News Today. February 28, 2004. http://www.medicalnewstoday.com/articles/6225.php. Accessed July 16, 2009.
23. Walmart. New Wal-Mart program broadens access to affordable prescriptions in Michigan. May 5, 2009. http://walmartstores.com/pressroom/news/9118.aspx. Accessed August 25, 2009.
24. Fein AJ. New details on WMT-CAT pharmacy deals. Drug Channels. November 6, 2008. http://www.drugchannels.net/2008/11/new-details-on-wmt-cat-pharmacy-deal.html. Accessed August 25, 2009.
25. Walmart expands low-cost prescription drug program. The Business Journal of Milwaukee. August 18, 2009. http://milwaukee.bizjournals.com/milwaukee/stories/2009/08/17/daily25.html. Accessed August 25, 2009.
26. Rubenstein S. Wal-Mart tries to step on pharmacy-benefit managers' turf. Health Blog. The Wall Street Journal. May 4, 2009. http://blogs.wsj.com/health/2009/05/04/wal-mart-tries-to-step-on-pharmacy-benefit-managers-turf/tab/article/. Accessed February 15, 2010.
27. Felland LE, Reschovsky JD. More nonelderly Americans face problems affording prescription drugs. Track Rep. 2009(22):1-4.
28. Chisholm MA, DiPiro JT. Pharmaceutical manufacturer assistance programs. Arch Intern Med. 2002;162(7):780-784.
29. Heisler M, Wagner TH, Piette JD. Patient strategies to cope with high prescription medication costs: who is cutting back on necessities, increasing debt, or underusing medications? J Behav Med. 2005;28(1):43-51.
30. Mounts VL, Ringenberg DG, Rhees K, Partridge C. Implementation of a patient medication assistance program in a community pharmacy setting. J Am Pharm Assoc (2003). 2005;45(1):76-81.
31. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27(2):384-391.
32. Wagner TH, Heisler M, Piette JD. Prescription drug co-payments and costrelated medication underuse. Health Econ Policy Law. 2008;3(pt 1):51-67.
33. Gottlieb JL. Helping low-income patients obtain prescription medications. Arch Ophthalmol. 2002;120(11):1575-1576.
34. Patel UD, Davis MM. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans. J Am Soc Nephrol. 2006;17(9):2546-2553.
35. Clay P, Vaught E, Glaros A, Mangum S, Hansen D, Lindsey C. Costs to physician offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs. J Manag Care Pharm. 2007;13(6):506-514.
36. Harmon GN, Lefante J, Roy W, et al. Outpatient medication assistance program in a rural setting. Am J Health Syst Pharm. 2004;61(6):603-607.
37. Sarrafizadeh M, Waite NM, Hobson EH, Migden H. Pharmacist-facilitated enrollment in medication assistance programs in a private ambulatory care clinic. Am J Health Syst Pharm. 2004;61(17):1816-1820.
38. Reschovsky JD, Felland LE. Access to prescription drugs for Medicare beneficiaries. Track Rep. 2009;(23):1-4.
39. Cronk A, Humphries TL, Delate T, Clark D, Morris B. Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold. Am J Health Syst Pharm. 2008;65(11):1062-1070.
40. Stuart B, Simoni-Wastila L, Chauncey D. Assessing the impact of coverage gaps in the Medicare Part D drug benefit. Health Aff (Millwood). 2005;Suppl Web Exclusives:W5-167-W5-179.
41. Hoffman JM, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures-2009. Am J Health Syst Pharm. 2009;66(3):237-257.
42. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009;28(2):w317-w325.
43. Zhang JX, Yin W, Sun SX, Alexander GC. The impact of the Medicare Part D prescription benefit on generic drug use. J Gen Intern Med. 2008;23(10):1673-1678.